Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report highlights the importance of suspecting underlying malignancy, such as Hodgkin's lymphoma, in patients with diffuse hair loss and other cutaneous symptoms.

This case report describes a 46-year-old male whose alopecia areata preceded and resolved with treatment for stage IVB classical Hodgkin's lymphoma, highlighting AA as a potential indicator of underlying malignancy, although such cases are rare and not well-characterized.

This report describes a case of a man developing hair changes, including Beau's lines and Pohl-Pinkus constrictions, following ABVD chemotherapy.

This report describes a rare case where scalp alopecia manifested several months before the diagnosis of Hodgkin disease and discusses other similar cases in the literature.

This case report details an atypical presentation of Hodgkin's lymphoma in an 87-year-old man, where severe hypercalcemia and mental status changes prompted further investigation and diagnosis.

This study reported that Rapp-Hodgkin syndrome, AEC syndrome, and EEC syndrome are likely part of a single genetic disorder spectrum linked to mutations in the TP63 gene.

In this study, patients receiving CHOP chemotherapy for aggressive non-Hodgkin's lymphoma reported a wide range of side effects, with all experiencing hair loss by cycle 3 and fatigue as a common issue.

This meta-analysis reported that individuals who frequently use hair dye or have used it for over 20 years have an increased risk of developing non-Hodgkin's lymphoma.

This report describes two cases of Rapp–Hodgkin ectodermal dysplasia where refractory scalp erosions improved significantly with potent topical steroids; it also suggests a potential link between these scalp conditions and erosive pustular dermatosis of the scalp in elderly patients.

In this case report, a patient with Hodgkin's disease treated with ABVD chemotherapy became disease-free, and accompanying granuloma annulare skin lesions also improved.

This study suggests that the combination of bendamustine and rituximab is at least as effective and possibly offers a better therapeutic index than other standard regimens as first-line treatment for certain lymphoma patients.

This article presents a case of primary adrenal localization of non-Hodgkin's lymphoma in a 70-year-old woman, detailing her diagnosis and treatment, with no signs of recurrent disease after polychemotherapy and radiotherapy.

This study reported that VCP combination chemotherapy achieved a complete response in 53% of advanced non-Hodgkin's lymphoma patients, although more intensive treatment may be needed for improved outcomes.

This study found that in patients with AIDS-related non-Hodgkin lymphoma undergoing targeted therapy, a positive serum albumin change rate was significantly associated with better treatment outcomes, suggesting the value of dynamic albumin monitoring and nutritional support during treatment.

This report describes a case where severe hair loss occurred as an early manifestation of Hodgkin disease, with the literature suggesting it might result from follicle destruction or toxic effects.

This review discusses various treatment challenges and toxicities in patients with relapsed follicular lymphoma and suggests that novel therapies could improve outcomes by reducing exposure to harmful chemotherapy cycles.

This study found that 86% of patients with follicular non-Hodgkin's lymphoma were alive and nearly two-thirds remained in complete remission eight years after initial treatment with the radioimmunotherapy drug Bexxar.

In this study, both VEPA and ML-Y1 treatment regimens for older patients with non-Hodgkin's lymphoma showed similar response and survival rates, but neither was sufficient, indicating the need for a more effective approach.

This review suggests that bendamustine, alone or in combination, shows effectiveness in treating indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia, with recent studies highlighting its benefits especially in combination therapies, while balancing efficacy with a favorable toxicity profile.

In this randomized study, patients with early favorable Hodgkin lymphoma showed similar complete remission and survival rates whether receiving 2 or 4 cycles of ABVD and 20 Gy or 30 Gy IFRT, though reduced toxicity was associated with fewer cycles and lower radiation doses.

This study found that the PVP protocol, combining Peptichemio, vincristine, and 6-methylprednisolone, resulted in remission for diffuse non-Hodgkin's lymphomas with moderate side effects.

This study found that nearly 40% of Hodgkin’s Lymphoma patients who received Brentuximab Vedotin with AVD chemotherapy experienced persistent alopecia more than two years after treatment, leading to significant psychosocial consequences such as reduced self-confidence and emotional distress.

This study found that alopecia areata was associated with an increased risk of hematological malignancies, particularly non-Hodgkin lymphoma, but not with solid malignancies, except in certain severe cases.

This letter critiques a review of distant healing studies, highlighting significant methodological issues and limited evidence for its efficacy.

Patients with cutaneous lupus erythematosus have a higher risk of skin cancer and other cancers.

This article discusses the discontinuation of the Bexxar regimen for non-Hodgkin's lymphoma, noting that despite its effectiveness, it was under-prescribed due to marketing and development challenges without reporting new clinical results.

In this case report, a late preterm male infant presented with a pathogenic TP63 gene variant, consistent with Rapp-Hodgkin Syndrome, showing symptoms such as ichthyosiform erythroderma, cleft palate, and ankyloblepharon, highlighting the complex management and diagnostic challenges in such cases.

In this study, CHOP chemotherapy for intermediate grade Non-Hodgkin's Lymphoma showed predictable toxicities but was generally well tolerated without treatment interruption among most patients.

This study reported a 74% overall response rate for a new combination chemotherapy of mitoxantrone, etoposide, and prednisolone in patients with relapsed or refractory Hodgkin's disease or non-Hodgkin's lymphoma.

This case report discusses an instance of cystitis caused by the chemotherapy drug Cytoxan, with no new findings reported.